Results 211 to 220 of about 35,545 (253)

The clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Khan MS, Hashmi TM, Jehangir H, Akram MF, Munawar I, Jagani SD, Maqsood M, Khalid A, Ijaz M, Saeed U, Jafar U, Ehsan M, Tuglo LS, Rehman WU, Sabouni MA, Braiteh N, Yarkoni A, Patel K.   +17 more
europepmc   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

Effects of sodium-glucose co-transporter-2 inhibitors on the risk of nephrolithiasis and urinary tract infections in Thai patients with type 2 diabetes: a hospital-based cohort study. [PDF]

Diabetol Metab Syndr
Lukkunaprasit T, Tansawet A, Siriyotha S, Looareesuwan P, Yang J, Kunakorntham P, Sirisreetreerux P, Anothaisintawee T, McKay GJ, Attia J, Thakkinstian A.   +10 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near. [PDF]

Front Pediatr
Portalatin GM, Hong-McAtee I, Burgner AM, Gould ER, Hunley TE.   +4 more
europepmc   +1 more source

Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review. [PDF]

Ann Med Surg (Lond)
Fawwad SH, Patel MS, Dziugieł S, Alfaki R, Tamoor Akhtar Shaikh M, Khanal K, Lamichhane P, Barali S.   +7 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs. [PDF]

J Vet Med Sci
Umezawa M, Fujii Y, Orito K, Yoshimoto R.   +3 more
europepmc   +1 more source

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure. [PDF]

J Cardiovasc Dev Dis
Jurin I, Ivanović Mihajlović V, Šakić Z, Pavlov M, Šipić T, Vitlov P, Falak H, Grizelj D, Manola Š, Udovičić M.   +9 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus.

Indian J Pharmacol
Bellapu D, Darwin R.
europepmc   +1 more source

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis

Journal of Cellular Physiology, 2022
AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +5 more
openaire   +2 more sources